Looks like you clickedhttps://ir.ambrx.com/news/news-details/2023/Ambrx-Announces-ARX517-a-PSMA-Targeted-ADC-Demonstrates-a-Promising-52-PSA50-50-Reduction-and-a-Highly-Differentiated-Safety-and-PK-Profile-in-Patients-with-mCRPC-who-Progressed-on-Multiple-FDA-Approved-Treatments/default.aspx
If you do not want to visit that page, you can close this browser tab.
